Bellevue, WA[June,13th,2025] — PagodaTree Partners, a venture capital firm focused on innovation at the intersection of life sciences and technology, today announced its investment in Syndeio Biosciences, a clinical-stage biotechnology company pioneering synapse-targeted therapeutics for mental health and central nervous system (CNS) disorders.
Formerly operating as Gate Neurosciences, the company recently completed a merger with Boost Neuroscience and has rebranded as Syndeio Biosciences. The combined entity integrates Boost’s proprietary Boost? Synapse Pharmacology Platform and world-class scientific founding team, including Nobel Laureate Dr. Thomas C. Südhof (Stanford University), to address neurological and psychiatric diseases through synaptic repair and restoration.
Syndeio’s clinic pipeline includes leading asset Zelquistinel, A Phase 2-stage compound for major depressive disorder (MDD), now advancing into a biomarker-driven study for Alzheimer’s disease—representing a first-in-category approach to cognitive impairment in the whole world. Apimostinel, A differentiated NMDAR modulator currently under investigation in an investigator-led Phase 2 trial for acute depression.
Syndeio has raised $90 million in total funding to date. The latest round was supported by a high-caliber syndicate of institutional and strategic investors. In addition to PagodaTree Partners, investors include:M Capital（Merck VC）, Catalio Capital(backed by KKR), Innoviva, Tenmile, Luson Bioventures, and Palo Santo.
Syndeio also continues to receive strategic support from existing investors Eli Lilly and AbbVie, underscoring strong industry confidence in the company’s synaptic biology platform and its potential to deliver breakthrough therapeutics for CNS disorders.
“Syndeio represents a new frontier in neurotherapeutics, leveraging synaptic biology to tackle some of the most debilitating and underserved brain disorders,” said by Yancen Lu, CEO of PagodaTree Partners. “We are proud to partner with this world-class team as they pioneer a novel treatment paradigm for depression, Alzheimer’s disease, and beyond.”
With an experienced leadership team and a platform grounded in decades of foundational neuroscience, Syndeio is uniquely positioned to transform the treatment landscape for mental health and neurodegenerative diseases.
About PagodaTree Partners
PagodaTree Partners is a venture capital firm investing in breakthrough innovations across life sciences and technology. The firm backs visionary entrepreneurs building transformative companies at the convergence of biology, data, and engineering.
Media Contact
[Charles Li]
[charlesli@pdtree.com]